<code id='F5F80400D3'></code><style id='F5F80400D3'></style>
    • <acronym id='F5F80400D3'></acronym>
      <center id='F5F80400D3'><center id='F5F80400D3'><tfoot id='F5F80400D3'></tfoot></center><abbr id='F5F80400D3'><dir id='F5F80400D3'><tfoot id='F5F80400D3'></tfoot><noframes id='F5F80400D3'>

    • <optgroup id='F5F80400D3'><strike id='F5F80400D3'><sup id='F5F80400D3'></sup></strike><code id='F5F80400D3'></code></optgroup>
        1. <b id='F5F80400D3'><label id='F5F80400D3'><select id='F5F80400D3'><dt id='F5F80400D3'><span id='F5F80400D3'></span></dt></select></label></b><u id='F5F80400D3'></u>
          <i id='F5F80400D3'><strike id='F5F80400D3'><tt id='F5F80400D3'><pre id='F5F80400D3'></pre></tt></strike></i>

          Home / fashion / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:14
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In